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1Pulmonary arterial hypertension (PAH) comprises a range of diseases defined by a resting mean pulmonary artery 
pressure (PAP) of ≥25 mm Hg.1 Disease pathology is char-
acterized by vasoconstriction and pulmonary vascular remod-
eling. Treatment options are limited to pharmacological 
vasodilatation via the prostacyclin, endothelin or nitric oxide 
pathways, or lung transplantation.2 Although there have been 
significant improvements in outcome over the past 2 decades, 
PAH remains a life shortening condition and survival at 3 
years is 68%.1 There is a clear and pressing need for novel 
treatment strategies.
See Editor’s Perspective by Leopold
Autonomic regulation of pulmonary vasculature tone is 
well recognized, but its role in PAH is less clearly defined. 
Increased plasma norepinephrine,3,4 muscle sympathetic nerve 
activity,5,6 and vessel sympathetic nerve endings7 have been 
demonstrated in patients with idiopathic PAH, identifying the 
neurohormonal axis as a potential therapeutic target.
The sympathetic hyperactivity observed in patients with 
PAH is partially chemoreflex mediated,5 but the contribu-
tion of other physiological mechanisms cannot be excluded.8 
Baroreceptors at the pulmonary artery bifurcation and along 
the large pulmonary arteries activate afferent fibers carried in 
the adventitia, which together with effector fibers in the muscle 
layer form a pulmo-pulmonary baroreceptor reflex.9 Surgical 
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disruption of these fibers has been shown to prevent rises in 
PAP induced by balloon occlusion8,10; however, the relative 
contribution of basal sympathetic tone and baroreceptor stim-
ulation to effector fiber activity is unclear. The development 
of percutaneous methods of arterial denervation now permits 
investigation of pulmonary artery denervation (PDN) as a 
treatment for PAH. The benefit of PDN has been shown in pre-
clinical11 and early clinical studies.12 The distribution of nerves 
around the pulmonary arteries, the mechanism of action, and 
the effect of radiofrequency ablation on the pulmonary artery 
wall are unknown. The immediate changes in PAP observed in 
preclinical11 and clinical studies12 of PDN cannot be explained 
by altered remodeling of the distal pulmonary arteries which 
therefore suggests an effect on vascular constriction. We there-
fore aimed to examine nerve distribution around the pulmonary 
arteries, demonstrate the effect of PDN in an acute vasocon-
strictive model of pulmonary hypertension (PH), and to show 
histological evidence of radiofrequency ablation on the nerves 
within the pulmonary artery adventitia.
Methods
Anatomic Distribution of Nerves Surrounding the 
Pulmonary Artery
To determine the anatomic relationship of nerve tissue to the pulmo-
nary artery, histological samples were prepared from Yorkshire white 
swine. Animals were sedated by intramuscular injection of azaperone 
(6–8 mg/kg) and euthanized by intravenous injection of phenobarbital 
WHAT IS KNOWN
•	Sympathetic tone is increased in patients with pul-
monary arterial hypertension.
•	 Increased sympathetic tone has been associated with 
elevated pulmonary artery pressures.
WHAT THE STUDY ADDS
•	Documents the distribution and depth of nerves sur-
rounding the pulmonary artery in an animal model.
•	Demonstrates the acute effect of radiofrequency en-
ergy delivery to the pulmonary artery wall.
•	Demonstrates the efficacy of pulmonary artery dener-
vation in an acute model of pulmonary hypertension.
Figure 1. Pulmonary artery (PA) nerve distribution. A, Volume reconstruction of the pulmonary arteries. Main pulmonary artery plane and 
right and left pulmonary artery plane represent the levels at which histological sections were taken for evaluation of nerve distribution. B–D, 
Idealized representation of nerve distribution around the main (B) and right (C) and left pulmonary arteries (D). Gray points represent single 
nerves, and blue points represent nerve trunks (n=3).
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(40 mg/kg) in accordance with The Animals (Scientific Procedures) 
Act 1986 under UK Home Office Project License 40/3722. The chest 
was opened via a midline thoracotomy and the pleura and pericardi-
um dissected to expose the heart and great vessels. The inferior vena 
cava, superior vena cava, and descending aorta were cross-clamped, 
and the heart and lungs were mobilized and excised en bloc (Figure 
IA and IB in the Data Supplement).
For anatomic studies of nerve distribution, the pulmonary arter-
ies were excised with local structures in place (Figure IA–IG in the 
Data Supplement). Tissue was washed in PBS and fixed overnight 
in 10% formalin. Axial tissue sections were cut post fixation, dehy-
drated in graded alcohols, and paraffin embedded. Five micrometer 
sections were mounted and stained with hematoxylin and eosin and 
S100 protein (Z0311, Dako). Blocks were trimmed to obtain repre-
sentative axial sections of the main pulmonary artery and the left and 
right pulmonary arteries beyond the bifurcation (Figure IC–IG in the 
Data Supplement). Anatomic orientation was determined from local 
structures. Images were acquired on a scanning microscope (10× ob-
jective, Axiocam 506 Color, Zeiss, Germany) and analysis performed 
in Zen 2 Blue Edition (Zeiss, Germany). Each artery was divided into 
4 equal anatomic quadrants (anterior, posterior, medial and lateral, or 
left and right as appropriate), and S100 and hematoxylin and eosin–
stained sections used to identify nerves (Figure IE–IG in the Data 




), and distance from lu-
minal aspect of the pulmonary artery wall (d) were measured for each 




) was plotted for each quad-
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was plotted as (θ, d) using the polar scatter plot function of the Plotly 
package (https://github.com/ropensci/plotly; http://plot.ly) in the open 
source programming language R (http://www.R-project.org/). Nerve 
distribution plots of idealized vessels were constructed from quadrant 
distribution plots in Photoshop CS6 (Adobe) at the level of the main 
pulmonary artery and the left and right pulmonary artery.
Interventional Experimental Study Design
Eight Yorkshire white pigs (21–27.5 kg) were assigned to PDN or 
sham procedure. Under anesthesia (intramuscular azaperone, 40 mg/
mL at 6 mg/kg; intravenous propofol, 10 mg/mL at 3 mg/kg; and iso-
flurane, 2% to 3% in 100% O2 via endotracheal tube), left and right 
heart catheterizations were performed with radiographic guidance (BV 
Pulsera, Philips). Following baseline hemodynamic measurements, 
stable thromboxane A2 agonist13 (TxA2, D0400, Sigma-Aldrich) was 
infused via a 6F sheath in the right internal jugular vein. The dose of 
infused TxA2 was increased at 5-minute intervals in accordance with 
defined protocol (10 μg/mL at 17, 22, 27, 32, and 37 μg/kg per hour) 
determined from preliminary experiments (data not shown). Each ani-
mal received the same escalating dose of TxA2 at the same time inter-
val. Once maximum PAP was attained, TxA2 was discontinued. When 
PAP returned to baseline, PDN or a sham procedure was performed. 
To assess the efficacy of PDN, the infusion of TxA2 was repeated post 
procedure using the same TxA2 challenge protocol.
Hemodynamic Measurements
Pulmonary hemodynamics were monitored via Swan Ganz catheter 
(Baxter Healthcare) and systemic arterial pressures via a 6F multipur-
pose catheter (Medtronic Inc). Cardiac output (CO) was measured by 
thermodilution and pulmonary vascular resistance (PVR) calculated 
as PVR=(mean PAP−LVEDP)/CO.
PDN and Sham Procedure
PDN was performed using a modified prototype radiofrequency cath-
eter and G2 generator (Medtronic Inc). A 6F catheter was advanced 
to the pulmonary artery bifurcation. A spiral configuration of 8 suc-
cessful ablations was performed along the right and left pulmonary 
arteries (temperature >55°C; impedance reduction >10%; ablation 
duration >1 minute). The procedure was developed based on the 
anatomic location of nerves around the pulmonary arteries, the fea-
sibility of catheter access to the pulmonary artery wall, and known 
parameters of radiofrequency energy delivery. For each ablation, the 
PDN catheter, on a 0.014″ guidewire, was positioned distal to the 
intended point of denervation. Withdrawal of the guidewire allowed 
the catheter to reform its resting conformation and apposed the elec-
trode to the luminal aspect of the pulmonary artery. The bifurcation 
of the main pulmonary artery and the ostium of the basal segmental 
branches were used as proximal and distal anatomic markers for the 
procedure. Fluoroscopy and impedance were used to guide catheter 
positioning and confirm contact of the electrode with the pulmonary 
artery wall. Continuous monitoring of output, temperature, and im-
pedance was used to monitor and optimize each ablation (Figure II 
in the Data Supplement). The sham procedure was performed using 
a dummy catheter that did not deliver radiofrequency energy. The 
first challenge of TxA2 was performed, and hemodynamic parameters 
were allowed to return to baseline. The catheter was advanced to the 
point of denervation and the generator activated; however, no radio-
frequency energy was delivered. The second challenge of TxA2 was 
performed as previously described.
Examination of the Pulmonary Artery After PDN
For histological examination of the pulmonary artery postablation, tis-
sue was excised as previously described, and the pulmonary arteries dis-
sected from surrounding tissue from the pulmonary valve distally. The 
luminal surface of the pulmonary artery was exposed via an anterior 
Figure 2. Experimental model of pulmonary hypertension. A, The 
dose of thromboxane A2 agonist (TxA2) was increased at 5-min-
ute interval (0–37 μg/kg per hour) and then stopped. Once mean 
pulmonary artery pressure (mPAP) had returned to baseline, pul-
monary artery denervation or a sham procedure was performed, 
and the TxA2 infusion was repeated. B, Stepped infusion of TxA2 
gives a reproducible dose-dependent increase in systolic (sPAP), 
mean (mPAP) and diastolic PAP (dPAP) (n=8, mean±SEM).
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incision and tissue prepared en face. Ablation points were identified by 
the presence of blisters on the luminal aspect of the pulmonary artery. 
Sections were prepared as previously described and stained for hema-
toxylin and eosin, Alcian blue Elastin/van Gieson (ABEVG), S100 
protein (Z0311, Dako), and α-smooth muscle actin (M0851, Dako).14
Statistical Analysis
Data are expressed as mean±SEM. Differences between data sets 
were assessed by 2-way ANOVA with Sidak’s correction for multiple 
comparison or Student t test as appropriate in Prism 6.0 for Macintosh 
(GraphPad Software).
Results
Nerve Distribution of the Pulmonary Artery
To map nerve distribution, the pulmonary arteries (main pul-
monary artery and left and right pulmonary artery) of 3 York-
shire white swine were evaluated histologically. At the level 
of the main pulmonary artery (Figure 1A), there was circum-
ferential distribution of nerves (Figure 1B) that were limited 
to the anterior and right side by the pericardial reflection and 
adventitia of the great vessels (Figure IC and IE in the Data 
Supplement). The majority of nerves were located between 1 
and 3 mm from the endothelial aspect of the pulmonary artery 
wall and were of a greater diameter than those located more 
distally (Figure 1A; Figure IH and II in the Data Supplement). 
Distal to the pulmonary artery bifurcation nerves (Figure 1A) 
were distributed circumferentially around the right and left 
pulmonary artery. Nerves were greater in number, smaller in 
size, and located in closer proximity to the luminal aspect of 
pulmonary artery wall (<1 mm) than those at the level of the 
main pulmonary artery (Figure 1B–D; Figure IH and II in the 
Data Supplement). The number of nerves in close proximity to 
the right pulmonary artery was greater than the left pulmonary 
artery (Figure 1C and 1D). Discrete nerve bundles were iden-
tified >3 mm posterior and right of the main pulmonary artery 
and posterior and lateral of the right pulmonary artery (Fig-
ure 1B and 1C).
TxA2 Induces Acute PH in a Porcine Model
To determine the effect of PDN on PH, an acute TxA2 swine 
model of PH was established.13 Infusion of TxA2 led to a 
reproducible, dose-dependent rise in PAP (Figure 2A and 2B). 
Cessation of TxA2 infusion resulted in the PAP returning to 
baseline (Figure 2A). Repeated infusion of TxA2 increased 
PAP in a manner comparable with the initial infusion (Fig-
ure 2A), thereby establishing a robust model to test the effi-
cacy of PDN (Figure 3).
Acute Safety
Animals remained hemodynamically stable throughout the 
procedure. No adverse events were identified as a result of 
administration of TxA2 or PDN.
PDN Reduces Mean PAP in an Acute Porcine Model 
of PH
There was no significant difference in hemodynamic response 
to the first infusion TxA2 between groups selected for PDN or 
Sham treatment (Figure 4A–4F). Both PDN and Sham-treated 
animals developed PH in response to TxA2 as demonstrated 
by mean PAP (mPAP) of >40 mm Hg (Figure 4A). Consis-
tent with the observed change in mPAP, CO was decreased 
and PVR increased during the induction of PH in both groups 
(Figure 4C and 4D). Maximum mPAP was comparable 
between first and second TxA2 challenge in the Sham group; 
Figure 3. Pulmonary artery denervation 
(PDN) catheter and procedure. Prototype 
radiofrequency catheter (Medtronic Inc) 
off (A) and on (B) a 0.014″ guidewire (F 
indicates nitinol Spyral; S, catheter shaft; 
arrow, radiofrequency electrode; scale 
increment 1 mm). C, Pulmonary artery 
angiogram. White lines represent the proxi-
mal and distal boundaries for PDN pro-
cedure. Proximal (P) indicates pulmonary 
artery bifurcation; left distal (DL), ostium of 
the posterior artery; and right distal (DR), 
posterior descending artery (disc: 26 mm). 
Fluoroscopy of the PDN catheter in the 
right (D) and left pulmonary artery (E).
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however, PDN resulted in a reduction in mPAP from first to 
second TxA2 challenge in the PDN group and between the 
Sham and PDN group during the second TxA2 challenge (Fig-
ure 4A). The difference in mPAP was further emphasized by 
the reduction of area under the curve of mPAP against time 
from first to second TxA2 challenge in the PDN group and 
between the Sham and PDN group during the second TxA2 
challenge (Figure 4B). Consistent with the pressure changes 
identified, PDN resulted in improved CO and PVR (Figure 4C 
and 4D). PDN did not alter left ventricular systolic or left ven-
tricular end diastolic pressure (Figure 4E and 4F).
PDN Induces Acute Histological Changes and 
Reduces Adventitial Nerve Staining
Ablation lesions were visible on the luminal aspect of the 
pulmonary artery of each animal in the PDN group (Figure 
5A), and the number of lesions correlated with hemodynamic 
response (Figure 5B). Microscopic examination of denerva-
tion lesions identified intimal disruption and thrombus (Fig-
ure 5C and 5E) with linear elastic laminae (fixed within area 
of thermal damage), reduced medial thickness (Figure 5C, 
5D, 5F, and 5G), and altered adventitial architecture (Figure 
5C and 5E). There was also a reduction in the expression of 
the nerve-associated S100 protein (Figure 5I and 5J). The 
observed acute histological changes were consistent between 
animals and between lesions (Figure 5H and 5K).
Discussion
This study maps the location and depth of the nerve distribu-
tion of the pulmonary arteries and demonstrates, using a pro-
totype radiofrequency catheter and generator, that PDN alters 
the structure of nerves supplying the pulmonary arteries and 
results in a dose-dependent improvement in pulmonary hemo-
dynamics. The acute reduction in PAP achieved with PDN 
suggests that there is a sympathetic contribution to vasocon-
striction in PH that may be therapeutically tractable.
The distribution and function of nerves supplying the pul-
monary arteries has been documented in a range of animals15; 
however, data relating anatomic location to nerve depth has not 
previously been reported. We identified nerve fibers and trunks 
at the level of the main pulmonary artery and left and right pul-
monary arteries with marked variation in vessel wall thickness, 
nerve depth, and nerve diameter at each level. The depth of his-
tological changes induced by radiofrequency energy delivery 
varied with anatomic location and wall thickness. In arteries 
with a greater medial component, such as the aorta or proximal 
pulmonary artery, there was little or no histological effect of 
radiofrequency energy delivery on nerve S100 protein staining, 
indicating that the location and technical parameters of energy 
delivery are critical to successful PDN. Further anatomic and 
physiological investigation of nerve distribution and function 
is clearly required to improve understanding of the therapeutic 
mechanism of action and enable procedural optimization.
Figure 4. Experimental study hemodynamics. 
A, Mean pulmonary artery pressure (mPAP) at 
baseline and maximum thromboxane A2 agonist 
(TxA2) pre (TxA2-1) and post (TxA2-2) procedure for 
sham- and pulmonary artery denervation (PDN)-
treated animals. B, Area under the curve (AUC) of 
time–pressure for PDN- and sham-treated animals 
during the pre and post procedure TxA2 challenges, 
cardiac output (CO; C), pulmonary vascular resis-
tance (PVR; D), LVSP (E), and LVEDP (F) at base-
line and maximum TxA2 pre and post procedure for 
sham- and PDN-treated animals. PDN, n=5; Sham, 
n=3; mean±SEM. LVEDP indicates left ventricular 
end diastolic pressure; and LVSP, left ventricular 
systolic pressure. *P<0.05, **P<0.01, 2-way ANOVA 
with Sidak’s correction for multiple comparisons.
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Inflammation, cellular proliferation, and vasoconstriction 
all drive disease pathology in PAH16; however, the contribu-
tion of these underlying factors to the burden of disease in 
an individual patient is not known. Elevated plasma norepi-
nephrine,3,4 increased muscle sympathetic nerve activity,5,6 
and increased vessel sympathetic nerve endings7 in patients 
with idiopathic PAH have all been described, thus implicating 
sympathetic activity in disease. Modulation of the neurohor-
monal axis in PAH, using pharmacological17 and device-based 
therapies11 has shown benefit in experimental and early human 
studies.12 Further work is required to understand the role in 
disease pathology and establish the therapeutic mechanism. 
Previous PDN studies have demonstrated efficacy using a bal-
loon occlusion model,8,11 however, the mechanism by which 
PH is induced in that model remains controversial. Balloon 
occlusion is thought to cause an increase in PAP through acti-
vation of a pulmo-pulmonary baroreflex,9 but the extent to 
which this reflex contributes to human disease is unknown. 
Vasoconstriction is a fundamental mediator of disease pathol-
ogy in PAH. We therefore used a vasoconstriction-based 
model of PH13 and have demonstrated that PDN reduced PAP 
and PVR and increased CO, with a limited reduction of sys-
temic blood pressure. Our findings suggest that the innerva-
tion of the pulmonary vasculature contributes to PH in disease 
models beyond balloon occlusion. Although our findings 
do not fully replicate the complete prevention11 or reversal12 
of PH previously reported, the improvement in pulmonary 
hemodynamics achieved would be clinically meaningful. 
Figure 5. A, En face preparation of the pulmonary artery. Arrows indicate denervation lesions in the right pulmonary artery. B, Change in 
mean pulmonary artery pressure (mPAP) between first and second infusion of thromboxane A2 agonist (TxA2) plotted against the number 
of visible ablation lesions. C–E, Alcian blue Elastin/van Gieson (ABEVG)–stained artery sections (scale bar: 500 μm). C, Control pulmo-
nary artery, (D) denervation lesion in the pulmonary artery, and (E) denervation lesion in the aorta. F and G, Smooth muscle actin–stained 
pulmonary artery sections (scale bar: 500 μm). F, Control and (G) denervation lesion. H, The acute effect of pulmonary artery denervation 
(PDN) on wall medial thickness. I and J, S100 protein–stained sections showing nerves in the pulmonary artery adventitia (scale bar 20 
μm). I, Control and (J) denervation lesion. K, The acute effect of PDN on nerve S100 protein staining (n=5, mean±SEM, *P<0.05, paired 
Student t test).
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Although PDN has shown promising early results, it is criti-
cally important that the mechanistic effects of intervention are 
fully evaluated in the context of chronic disease.
Limitations
PH in the TxA2 model is induced by acute vascoconstric-
tion and not by progressive pulmonary vascular remodeling. 
The acute nature of the experiment precluded the evaluation 
of long-term effect on pulmonary hemodynamics and vessel 
histology. Although vasoconstriction plays a role in disease 
pathology and is a therapeutic target for the treatment of PAH, 
the improved hemodynamics demonstrated in this study may 
not translate directly to human disease.
Conclusions
In an acute vasoconstriction-based model of PH, we have pro-
vided a detailed description of the distribution of nerves in the 
proximal pulmonary vasculature. We have also demonstrated 
the efficacy of PDN and described the associated histological 
and biochemical changes. Further studies are required to opti-
mize the PDN procedure and to investigate the safety and the 
long-term efficacy of intervention before large clinical trials in 
patients are considered.
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